GLP-1 and semaglutide are not the same thing. GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally, while semaglutide is a pharmaceutical drug designed to mimic that hormone. The relationship is similar to the one between insulin (a natural hormone) and injectable insulin (a medication). Understanding the difference helps make sense of the drug names, brand names, and terminology you’ll encounter.
GLP-1: The Natural Hormone
GLP-1 is a hormone released by your gut after you eat. It does three things simultaneously: it signals your pancreas to release insulin, it tells your brain you’re full by activating satiety centers in the hypothalamus, and it slows the movement of food from your stomach into your small intestine. Together, these effects help regulate blood sugar and control appetite.
The catch is that natural GLP-1 breaks down almost immediately. It has a half-life of just one to two minutes, meaning your body clears it from the bloodstream within a few minutes of releasing it. That’s fine for normal digestion, but it makes the raw hormone useless as a medication. You can’t inject something that disappears in two minutes and expect it to treat a chronic condition like diabetes or obesity.
Semaglutide: An Engineered Version of GLP-1
Semaglutide is a GLP-1 receptor agonist, which means it activates the same receptors in your body that natural GLP-1 does. But its molecular structure has been modified so it resists breakdown. Where natural GLP-1 lasts one to two minutes, semaglutide has a half-life of about 165 hours, roughly a full week. That’s why it works as a once-weekly injection.
It triggers the same biological cascade as the natural hormone: more insulin when blood sugar is high, reduced appetite through the brain’s satiety pathways, and slower gastric emptying. The difference is duration and intensity. A weekly dose of semaglutide keeps those effects running continuously rather than in the brief post-meal bursts your body normally produces.
Three Brand Names, One Drug
Semaglutide is the active ingredient in three brand-name products, each approved for different uses:
- Ozempic is an injectable approved for managing type 2 diabetes and reducing the risk of heart attack and stroke. It is not FDA-approved for weight loss, despite its widespread reputation as a weight loss drug.
- Wegovy is an injectable approved for weight loss in adults and children aged 12 and older. In 2024, the FDA also approved it to reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease who also have obesity or are overweight.
- Rybelsus is an oral tablet (not an injection) approved for managing type 2 diabetes. It is not approved for weight loss.
All three contain semaglutide. The differences come down to dose, delivery method, and what the FDA has specifically approved each one to treat.
Semaglutide Is One of Several GLP-1 Drugs
Semaglutide isn’t the only GLP-1 receptor agonist on the market. The drug class includes several medications, each with its own dosing schedule and approved uses:
- Liraglutide (sold as Victoza for diabetes, Saxenda for weight loss), a daily injection
- Dulaglutide (Trulicity), a weekly injection for diabetes
- Exenatide (Byetta for twice-daily dosing, Bydureon BCise for weekly dosing)
- Tirzepatide (Mounjaro, Zepbound), which activates both the GLP-1 receptor and a second hormone receptor called GIP
When people refer to “GLP-1 medications” or “GLP-1 drugs,” they’re talking about this entire class. Semaglutide is the most well-known member, but it’s one option among several. Each works through the same core mechanism but differs in how long it lasts, how it’s taken, and what clinical evidence supports its use.
What the Cardiovascular Data Shows
One reason semaglutide gets so much attention is cardiovascular data that goes beyond blood sugar or weight. In a trial of more than 17,600 participants with heart disease and obesity or overweight, major cardiovascular events (heart attack, stroke, or cardiovascular death) occurred in 6.5% of participants taking semaglutide compared to 8% on placebo. Both groups also received standard heart-related care like blood pressure and cholesterol management. That 1.5 percentage point difference was significant enough for the FDA to grant Wegovy a dedicated cardiovascular indication, the first weight management drug to receive one.
How the Dose Builds Over Time
If you’re prescribed semaglutide for weight loss (Wegovy), you don’t start at the full dose. The schedule ramps up over about four months: 0.25 mg weekly for the first four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the maintenance dose of 2.4 mg weekly around week 17. This gradual increase exists to reduce gastrointestinal side effects like nausea, which are most common when the dose jumps. Your provider assesses how you’re responding at each step before moving to the next one.
Important Safety Considerations
Semaglutide carries a boxed warning about thyroid tumors. People with a personal or family history of medullary thyroid cancer, or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN2), should not use it. This warning applies to all three brand-name versions.
Other conditions that require careful discussion with a prescriber before starting semaglutide include a history of pancreatitis, gastroparesis or other severe stomach problems, gallbladder disease, kidney disease, and diabetic retinopathy. People with a history of depression or suicidal thoughts should also flag this, as mood changes have been reported. Allergic reactions to semaglutide or any of its inactive ingredients are another reason to avoid it.
The short version: GLP-1 is the natural hormone your body makes every time you eat. Semaglutide is a lab-engineered drug that copies what GLP-1 does but lasts roughly 5,000 times longer. The term “GLP-1 medications” refers to the whole family of drugs built on this principle, with semaglutide being the most prominent member.